Innate and Adaptive Immunity in Cystic Fibrosis

Clinics in Chest Medicine

Volumn 37, Issue 1, 2016, Pages 17-29

  Bruscia, Emanuela M ^a   Bonfield, Tracey L ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adaptive immunity; Bacterial infection; Innate immunity; Lung hyperinflammation

Indexed keywords

NITRIC OXIDE; PROTEINASE;

ACIDIFICATION; ADAPTIVE IMMUNITY; AIRWAY; CELL FUNCTION; CELL INTERACTION; CHEMICAL COMPOSITION; CYSTIC FIBROSIS; DISEASE ASSOCIATION; DOWN REGULATION; ENZYME ACTIVITY; HOST RESISTANCE; HUMAN; IMMUNE DYSREGULATION; IMMUNE SYSTEM; IMMUNOREGULATION; INNATE IMMUNITY; LUNG FUNCTION; LYMPHOCYTE; MACROPHAGE; MONOCYTE; MUCOCILIARY CLEARANCE; NEUTROPHIL; OXIDATIVE STRESS; PERMEABILITY BARRIER; PHAGOCYTE; PRIORITY JOURNAL; REVIEW; UPREGULATION; IMMUNOLOGY; RESPIRATORY TRACT MUCOSA;

ADAPTIVE IMMUNITY; CYSTIC FIBROSIS; HUMANS; IMMUNITY, INNATE; MUCOCILIARY CLEARANCE; RESPIRATORY MUCOSA;

EID: 84959500692     PISSN: 02725231     EISSN: 15578216     Source Type: Journal    
DOI: 10.1016/j.ccm.2015.11.010     Document Type: Review

References (148)

1. Knowles M.R., Boucher R.C. Mucus clearance as a primary innate defense mechanism for mammalian airways. J Clin Invest 2002, 109(5):571-577.
2. Bals R., Hiemstra P.S. Innate immunity in the lung: how epithelial cells fight against respiratory pathogens. Eur Respir J 2004, 23(2):327-333.
3. Pohl C., Hermanns M.I., Uboldi C., et al. Barrier functions and paracellular integrity in human cell culture models of the proximal respiratory unit. Eur J Pharm Biopharm 2009, 72(2):339-349.
4. Kreda S.M., Davis C.W., Rose M.C. CFTR, mucins, and mucus obstruction in cystic fibrosis. Cold Spring Harb Perspect Med 2012, 2(9):a009589.
5. Hoegger M.J., Fischer A.J., McMenimen J.D., et al. Impaired mucus detachment disrupts mucociliary transport in a piglet model of cystic fibrosis. Science 2014, 345(6198):818-822.
6. Quinton P.M. Role of epithelial HCO3(-) transport in mucin secretion: lessons from cystic fibrosis. Am J Physiol Cell Physiol 2010, 299(6):C1222-C1233.
7. Schutte A., Ermund A., Becker-Pauly C., et al. Microbial-induced meprin beta cleavage in MUC2 mucin and a functional CFTR channel are required to release anchored small intestinal mucus. Proc Natl Acad Sci U S A 2014, 111(34):12396-12401.
8. Boucher R.C. Airway surface dehydration in cystic fibrosis: pathogenesis and therapy. Annu Rev Med 2007, 58:157-170.
9. Lazarowski E.R., Tarran R., Grubb B.R., et al. Nucleotide release provides a mechanism for airway surface liquid homeostasis. J Biol Chem 2004, 279(35):36855-36864.
10. Yuan S., Hollinger M., Lachowicz-Scroggins M.E., et al. Oxidation increases mucin polymer cross-links to stiffen airway mucus gels. Sci Transl Med 2015, 7(276):276ra27.
11. Worlitzsch D., Tarran R., Ulrich M., et al. Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients. J Clin Invest 2002, 109(3):317-325.
12. Saini Y., Dang H., Livraghi-Butrico A., et al. Gene expression in whole lung and pulmonary macrophages reflects the dynamic pathology associated with airway surface dehydration. BMC Genomics 2014, 15:726.
13. Abou Alaiwa M.H., Reznikov L.R., Gansemer N.D., et al. pH modulates the activity and synergism of the airway surface liquid antimicrobials beta-defensin-3 and LL-37. Proc Natl Acad Sci U S A 2014, 111(52):18703-18708.
14. Rogan M.P., Taggart C.C., Greene C.M., et al. Loss of microbicidal activity and increased formation of biofilm due to decreased lactoferrin activity in patients with cystic fibrosis. J Infect Dis 2004, 190(7):1245-1253.
15. Ghio A.J., Roggli V.L., Soukup J.M., et al. Iron accumulates in the lavage and explanted lungs of cystic fibrosis patients. J Cyst Fibros 2013, 12(4):390-398.
16. Moreau-Marquis S., Coutermarsh B., Stanton B.A. Combination of hypothiocyanite and lactoferrin (ALX-109) enhances the ability of tobramycin and aztreonam to eliminate Pseudomonas aeruginosa biofilms growing on cystic fibrosis airway epithelial cells. J Antimicrob Chemother 2015, 70(1):160-166.
17. Pohl K., Hayes E., Keenan J., et al. A neutrophil intrinsic impairment affecting Rab27a and degranulation in cystic fibrosis is corrected by CFTR potentiator therapy. Blood 2014, 124(7):999-1009.
18. Britto C.J., Cohn L. Bactericidal/Permeability-increasing protein fold-containing family member A1 in airway host protection and respiratory disease. Am J Respir Cell Mol Biol 2015, 52(5):525-534.
19. Tarran R., Redinbo M.R. Mammalian short palate lung and nasal epithelial clone 1 (SPLUNC1) in pH-dependent airway hydration. Int J Biochem Cell Biol 2014, 52:130-135.
20. Goldstein W., Doring G. Lysosomal-enzymes from polymorphonuclear leukocytes and proteinase-inhibitors in patients with cystic-fibrosis. Am Rev Respir Dis 1986, 134(1):49-56.
21. Sagel S.D., Wagner B.D., Anthony M.M., et al. Sputum biomarkers of inflammation and lung function decline in children with cystic fibrosis. Am J Respir Crit Care Med 2012, 186(9):857-865.
22. Bruce M.C., Poncz L., Klinger J.D., et al. Biochemical and pathologic evidence for proteolytic destruction of lung connective tissue in cystic fibrosis. Am Rev Respir Dis 1985, 132(3):529-535.
23. Hartl D., Latzin P., Hordijk P., et al. Cleavage of CXCR1 on neutrophils disables bacterial killing in cystic fibrosis lung disease. Nat Med 2007, 13(12):1423-1430.
24. Vandivier R.W., Fadok V.A., Hoffmann P.R., et al. Elastase-mediated phosphatidylserine receptor cleavage impairs apoptotic cell clearance in cystic fibrosis and bronchiectasis. J Clin Invest 2002, 109(5):661-670.
25. Doring G. The role of neutrophil elastase in chronic inflammation. Am J Respir Crit Care Med 1994, 150(6 Pt 2):S114-S117.
26. Voynow J.A., Young L.R., Wang Y., et al. Neutrophil elastase increases MUC5AC mRNA and protein expression in respiratory epithelial cells. Am J Physiol 1999, 276(5 Pt 1):L835-L843.
27. Devaney J.M., Greene C.M., Taggart C.C., et al. Neutrophil elastase up-regulates interleukin-8 via toll-like receptor 4. FEBS Lett 2003, 544(1-3):129-132.
28. Rowe S.M., Heltshe S.L., Gonska T., et al. Network GIotCFFTD. Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis. Am J Respir Crit Care Med 2014, 190(2):175-184.
29. Weldon S., McNally P., McAuley D.F., et al. miR-31 dysregulation in cystic fibrosis airways contributes to increased pulmonary cathepsin S production. Am J Respir Crit Care Med 2014, 190(2):165-174.
30. Witko-Sarsat V., Halbwachs-Mecarelli L., Schuster A., et al. Proteinase 3, a potent secretagogue in airways, is present in cystic fibrosis sputum. Am J Respir Cell Mol Biol 1999, 20(4):729-736.
31. Gaggar A., Hector A., Bratcher P.E., et al. The role of matrix metalloproteinases in cystic fibrosis lung disease. Eur Respir J 2011, 38(3):721-727.
32. Galli F., Battistoni A., Gambari R., et al. Oxidative stress and antioxidant therapy in cystic fibrosis. Biochim Biophys Acta 2012, 1822(5):690-713.
33. Bogdan C. Nitric oxide and the immune response. Nat Immunol 2001, 2(10):907-916.
34. Grasemann H., Michler E., Wallot M., et al. Decreased concentration of exhaled nitric oxide (NO) in patients with cystic fibrosis. Pediatr Pulmonol 1997, 24(3):173-177.
35. Kelley T.J., Drumm M.L. Inducible nitric oxide synthase expression is reduced in cystic fibrosis murine and human airway epithelial cells. J Clin Invest 1998, 102(6):1200-1207.
36. Grasemann H., Schwiertz R., Matthiesen S., et al. Increased arginase activity in cystic fibrosis airways. Am J Respir Crit Care Med 2005, 172(12):1523-1528.
37. Grasemann H., Gonska T., Avolio J., et al. Effect of ivacaftor therapy on exhaled nitric oxide in patients with cystic fibrosis. J Cyst Fibros 2015, 14(6):727-732.
38. Kotha K., Szczesniak R.D., Naren A.P., et al. Concentration of fractional excretion of nitric oxide (FENO): a potential airway biomarker of restored CFTR function. J Cyst Fibros 2015, 14(6):733-740.
39. Coyne C.B., Vanhook M.K., Gambling T.M., et al. Regulation of airway tight junctions by proinflammatory cytokines. Mol Biol Cell 2002, 13(9):3218-3234.
40. Huang S., Jornot L., Wiszniewski L., et al. Src signaling links mediators of inflammation to Cx43 gap junction channels in primary and transformed CFTR-expressing airway cells. Cell Commun Adhes 2003, 10(4-6):279-285.
41. Molina S.A., Stauffer B., Moriarty H.K., et al. Junctional abnormalities in human airway epithelial cells expressing F508del CFTR. Am J Physiol Lung Cell Mol Physiol 2015, 309(5):L475-L487.
42. Weiser N., Molenda N., Urbanova K., et al. Paracellular permeability of bronchial epithelium is controlled by CFTR. Cell Physiol Biochem 2011, 28(2):289-296.
43. De Lisle R.C. Disrupted tight junctions in the small intestine of cystic fibrosis mice. Cell Tissue Res 2014, 355(1):131-142.
44. Losa D., Kohler T., Bacchetta M., et al. Airway epithelial cell integrity protects from cytotoxicity of Pseudomonas aeruginosa quorum-sensing signals. Am J Respir Cell Mol Biol 2015, 53(2):265-275.
45. Dudez T., Borot F., Huang S., et al. CFTR in a lipid raft-TNFR1 complex modulates gap junctional intercellular communication and IL-8 secretion. Biochim Biophys Acta 2008, 1783(5):779-788.
46. Bruscia E.M., Zhang P.-X., Satoh A., et al. Abnormal trafficking and degradation of TLR4 underlie the elevated inflammatory response in cystic fibrosis. J Immunol 2011, 186(12):6990-6998.
47. Chanson M., Derouette J.P., Roth I., et al. Gap junctional communication in tissue inflammation and repair. Biochim Biophys Acta 2005, 1711(2):197-207.
48. Asgrimsson V., Gudjonsson T., Gudmundsson G.H., et al. Novel effects of azithromycin on tight junction proteins in human airway epithelia. Antimicrob Agents Chemother 2006, 50(5):1805-1812.
49. Akira S., Uematsu S., Takeuchi O. Pathogen recognition and innate immunity. Cell 2006, 124(4):783-801.
50. Tirouvanziam R., de Bentzmann S., Hubeau C., et al. Inflammation and infection in naive human cystic fibrosis airway grafts. Am J Respir Cell Mol Biol 2000, 23(2):121-127.
51. Hubeau C., Puchelle E., Gaillard D. Distinct pattern of immune cell population in the lung of human fetuses with cystic fibrosis. J Allergy Clin Immunol 2001, 108(4):524-529.
52. Bonfield T.L., Panuska J.R., Konstan M.W., et al. Inflammatory cytokines in cystic fibrosis lungs. Am J Respir Crit Care Med 1995, 152(6 Pt 1):2111-2118.
53. Gaggar A., Rowe S.M., Matthew H., et al. Proline-Glycine-Proline (PGP) and High Mobility Group Box Protein-1 (HMGB1): potential mediators of cystic fibrosis airway inflammation. Open Respir Med J 2010, 4:32-38.
54. Rowe S.M., Jackson P.L., Liu G., et al. Potential role of high-mobility group box 1 in cystic fibrosis airway disease. Am J Respir Crit Care Med 2008, 178(8):822-831.
55. Khan T.Z., Wagener J.S., Bost T., et al. Early pulmonary inflammation in infants with cystic fibrosis. Am J Respir Crit Care Med 1995, 151(4):1075-1082.
56. Worgall T.S. Lipid metabolism in cystic fibrosis. Curr Opin Clin Nutr Metab Care 2009, 12(2):105-109.
57. Karp C.L., Flick L.M., Park K.W., et al. Defective lipoxin-mediated anti-inflammatory activity in the cystic fibrosis airway. Nat Immunol 2004, 5(4):388-392.
58. Ringholz F.C., Buchanan P.J., Clarke D.T., et al. Reduced 15-lipoxygenase 2 and lipoxin A4/leukotriene B4 ratio in children with cystic fibrosis. Eur Respir J 2014, 44(2):394-404.
59. Leggieri E., De Biase R.V., Savi D., et al. Clinical effects of diet supplementation with DHA in pediatric patients suffering from cystic fibrosis. Minerva Pediatr 2013, 65(4):389-398.
60. Maiuri L., Luciani A., Giardino I., et al. Tissue transglutaminase activation modulates inflammation in cystic fibrosis via PPARgamma down-regulation. J Immunol 2008, 180(11):7697-7705.
61. Ollero M., Junaidi O., Zaman M.M., et al. Decreased expression of peroxisome proliferator activated receptor gamma in cftr-/- mice. J Cell Physiol 2004, 200(2):235-244.
62. Chen J., Kinter M., Shank S., et al. Dysfunction of Nrf-2 in CF epithelia leads to excess intracellular H2O2 and inflammatory cytokine production. PLoS One 2008, 3(10):e3367.
63. Ribeiro C.M., Boucher R.C. Role of endoplasmic reticulum stress in cystic fibrosis-related airway inflammatory responses. Proc Am Thorac Soc 2010, 7(6):387-394.
64. Parker D., Cohen T.S., Alhede M., et al. Induction of type I interferon signaling by Pseudomonas aeruginosa is diminished in cystic fibrosis epithelial cells. Am J Respir Cell Mol Biol 2012, 46(1):6-13.
65. Zheng S., De B.P., Choudhary S., et al. Impaired innate host defense causes susceptibility to respiratory virus infections in cystic fibrosis. Immunity 2003, 18(5):619-630.
66. Zhou Y., Song K., Painter R.G., et al. Cystic fibrosis transmembrane conductance regulator recruitment to phagosomes in neutrophils. J Innate Immun 2013, 5(3):219-230.
67. Su X., Looney M., Su H., et al. Role of CFTR expressed by neutrophils in modulating acute lung inflammation and injury in mice. Inflamm Res 2011, 60(7):619-632.
68. Nauseef W.M., Borregaard N. Neutrophils at work. Nat Immunol 2014, 15(7):602-611.
69. Ingersoll S.A., Laval J., Forrest O.A., et al. Mature cystic fibrosis airway neutrophils suppress T cell function: evidence for a role of arginase 1 but not programmed death-ligand 1. J Immunol 2015, 194(11):5520-5528.
70. Murray P.J., Wynn T.A. Protective and pathogenic functions of macrophage subsets. Nat Rev Immunol 2011, 11(11):723-737.
71. Brennan S., Sly P.D., Gangell C.L., et al. Alveolar macrophages and CC chemokines are increased in children with cystic fibrosis. Eur Respir J 2009, 34(3):655-661.
72. Locati M., Mantovani A., Sica A. Macrophage activation and polarization as an adaptive component of innate immunity. Adv Immunol 2013, 120:163-184.
73. Griese M., Latzin P., Kappler M., et al. alpha1-Antitrypsin inhalation reduces airway inflammation in cystic fibrosis patients. Eur Respir J 2007, 29(2):240-250.
74. Meyer M., Huaux F., Gavilanes X., et al. Azithromycin reduces exaggerated cytokine production by M1 alveolar macrophages in cystic fibrosis. Am J Respir Cell Mol Biol 2009, 41(5):590-602.
75. Hofer T.P., Frankenberger M., Heimbeck I., et al. Decreased expression of HLA-DQ and HLA-DR on cells of the monocytic lineage in cystic fibrosis. J Mol Med (Berl) 2014, 92(12):1293-1304.
76. Lubamba B.A., Jones L.C., O'Neal W.K., et al. X-Box binding protein 1 modulates innate immune responses of cystic fibrosis alveolar macrophages. Am J Respir Crit Care Med 2015, [Epub ahead of print].
77. Zaman M.M., Gelrud A., Junaidi O., et al. Interleukin 8 secretion from monocytes of subjects heterozygous for the deltaF508 cystic fibrosis transmembrane conductance regulator gene mutation is altered. Clin Diagn Lab Immunol 2004, 11(5):819-824.
78. Andersson C., Zaman M.M., Jones A.B., et al. Alterations in immune response and PPAR/LXR regulation in cystic fibrosis macrophages. J Cyst Fibros 2008, 7(1):68-78.
79. Bonfield T.L., Hodges C.A., Cotton C.U., et al. Absence of the cystic fibrosis transmembrane regulator (Cftr) from myeloid-derived cells slows resolution of inflammation and infection. J Leukoc Biol 2012, 92(5):1111-1122.
80. Hartl D., Gaggar A., Bruscia E., et al. Innate immunity in cystic fibrosis lung disease. J Cyst Fibros 2012, 11(5):363-382.
81. Wright F.A., Strug L.J., Doshi V.K., et al. Genome-wide association and linkage identify modifier loci of lung disease severity in cystic fibrosis at 11p13 and 20q13.2. Nat Genet 2011, 43(6):539-546.
82. Aron Y., Polla B.S., Bienvenu T., et al. HLA class II polymorphism in cystic fibrosis. A possible modifier of pulmonary phenotype. Am J Respir Crit Care Med 1999, 159(5 Pt 1):1464-1468.
83. *1501 is regulated by vitamin D. PLoS Genet 2009, 5(2):e1000369.
84. Knutsen A.P. Immunopathology and immunogenetics of allergic bronchopulmonary aspergillosis. J Allergy (Cairo) 2011, 2011:785983.
85. Koehm S., Slavin R.G., Hutcheson P.S., et al. HLA-DRB1 alleles control allergic bronchopulmonary aspergillosis-like pulmonary responses in humanized transgenic mice. J Allergy Clin Immunol 2007, 120(3):570-577.
86. Abdulrahman B.A., Khweek A.A., Akhter A., et al. Autophagy stimulation by rapamycin suppresses lung inflammation and infection by Burkholderia cenocepacia in a model of cystic fibrosis. Autophagy 2011, 7(11):1359-1370.
87. Bunting M.M., Shadie A.M., Flesher R.P., et al. Interleukin-33 drives activation of alveolar macrophages and airway inflammation in a mouse model of acute exacerbation of chronic asthma. Biomed Res Int 2013, 2013:250938.
88. Knight R.A., Kollnberger S., Madden B., et al. Defective antigen presentation by lavage cells from terminal patients with cystic fibrosis. Clin Exp Immunol 1997, 107(3):542-547.
89. Hampton T.H., Stanton B.A. A novel approach to analyze gene expression data demonstrates that the DeltaF508 mutation in CFTR downregulates the antigen presentation pathway. Am J Physiol Lung Cell Mol Physiol 2010, 298(4):L473-L482.
90. Aalaei-Andabili S.H., Rezaei N. Toll like receptor (TLR)-induced differential expression of microRNAs (MiRs) promotes proper immune response against infections: a systematic review. J Infect 2013, 67(4):251-264.
91. Xu Y., Krause A., Limberis M., et al. Low sphingosine-1-phosphate impairs lung dendritic cells in cystic fibrosis. Am J Respir Cell Mol Biol 2013, 48(2):250-257.
92. Bhattacharya S., Ray R.M., Johnson L.R. Decreased apoptosis in polyamine depleted IEC-6 cells depends on Akt-mediated NF-kappaB activation but not GSK3beta activity. Apoptosis 2005, 10(4):759-776.
93. Ku C.S., Pham T.X., Park Y., et al. Edible blue-green algae reduce the production of pro-inflammatory cytokines by inhibiting NF-kappaB pathway in macrophages and splenocytes. Biochim Biophys Acta 2013, 1830(4):2981-2988.
94. Barnes P.J. Corticosteroid resistance in patients with asthma and chronic obstructive pulmonary disease. J Allergy Clin Immunol 2013, 131(3):636-645.
95. Amaru Calzada A., Todoerti K., Donadoni L., et al. The HDAC inhibitor Givinostat modulates the hematopoietic transcription factors NFE2 and C-MYB in JAK2(V617F) myeloproliferative neoplasm cells. Exp Hematol 2012, 40(8):634-645.e10.
96. Durham A.L., Wiegman C., Adcock I.M. Epigenetics of asthma. Biochim Biophys Acta 2011, 1810(11):1103-1109.
97. Halili M.A., Andrews M.R., Labzin L.I., et al. Differential effects of selective HDAC inhibitors on macrophage inflammatory responses to the Toll-like receptor 4 agonist LPS. J Leukoc Biol 2010, 87(6):1103-1114.
98. Serrador J.M., Cabrero J.R., Sancho D., et al. HDAC6 deacetylase activity links the tubulin cytoskeleton with immune synapse organization. Immunity 2004, 20(4):417-428.
99. Bartling T.R., Drumm M.L. Oxidative stress causes IL8 promoter hyperacetylation in cystic fibrosis airway cell models. Am J Respir Cell Mol Biol 2009, 40(1):58-65.
100. Bartling T.R., Drumm M.L. Loss of CFTR results in reduction of histone deacetylase 2 in airway epithelial cells. Am J Physiol Lung Cell Mol Physiol 2009, 297(1):L35-L43.
101. Saadane A., Soltys J., Berger M. Role of IL-10 deficiency in excessive nuclear factor-kappaB activation and lung inflammation in cystic fibrosis transmembrane conductance regulator knockout mice. J Allergy Clin Immunol 2005, 115(2):405-411.
102. Perez A., Issler A.C., Cotton C.U., et al. CFTR inhibition mimics the cystic fibrosis inflammatory profile. Am J Physiol Lung Cell Mol Physiol 2007, 292(2):L383-L395.
103. Regamey N., Tsartsali L., Hilliard T.N., et al. Distinct patterns of inflammation in the airway lumen and bronchial mucosa of children with cystic fibrosis. Thorax 2012, 67(2):164-170.
104. Tan H.L., Regamey N., Brown S., et al. The Th17 pathway in cystic fibrosis lung disease. Am J Respir Crit Care Med 2011, 184(2):252-258.
105. Hartl D., Griese M., Kappler M., et al. Pulmonary T(H)2 response in Pseudomonas aeruginosa-infected patients with cystic fibrosis. J Allergy Clin Immunol 2006, 117(1):204-211.
106. Hector A., Schafer H., Poschel S., et al. Regulatory T cell impairment in cystic fibrosis patients with chronic Pseudomonas infection. Am J Respir Crit Care Med 2015, 191(8):914-923.
107. Kreindler J.L., Steele C., Nguyen N., et al. Vitamin D3 attenuates Th2 responses to Aspergillus fumigatus mounted by CD4+ T cells from cystic fibrosis patients with allergic bronchopulmonary aspergillosis. J Clin Invest 2010, 120(9):3242-3254.
108. McGuire J.K. Regulatory T cells in cystic fibrosis lung disease. More answers, more questions. Am J Respir Crit Care Med 2015, 191(8):866-868.
109. Iannitti R.G., Carvalho A., Cunha C., et al. Th17/Treg imbalance in murine cystic fibrosis is linked to indoleamine 2,3-dioxygenase deficiency but corrected by kynurenines. Am J Respir Crit Care Med 2013, 187(6):609-620.
110. Mueller C., Braag S.A., Keeler A., et al. Lack of cystic fibrosis transmembrane conductance regulator in CD3+ lymphocytes leads to aberrant cytokine secretion and hyperinflammatory adaptive immune responses. Am J Respir Cell Mol Biol 2011, 44(6):922-929.
111. Moss R.B., Bocian R.C., Hsu Y.P., et al. Reduced IL-10 secretion by CD4+ T lymphocytes expressing mutant cystic fibrosis transmembrane conductance regulator (CFTR). Clin Exp Immunol 1996, 106(2):374-388.
112. Soltys J., Bonfield T., Chmiel J., et al. Functional IL-10 deficiency in the lung of cystic fibrosis (cftr(-/-)) and IL-10 knockout mice causes increased expression and function of B7 costimulatory molecules on alveolar macrophages. J Immunol 2002, 168(4):1903-1910.
113. Mayer-Hamblett N., Aitken M.L., Accurso F.J., et al. Association between pulmonary function and sputum biomarkers in cystic fibrosis. Am J Respir Crit Care Med 2007, 175(8):822-828.
114. Konstan M.W., Doring G., Heltshe S.L., Investigators and Coordinators of BI Trial 543.45, et al. A randomized double blind, placebo controlled phase 2 trial of BIIL 284 BS (an LTB4 receptor antagonist) for the treatment of lung disease in children and adults with cystic fibrosis. J Cyst Fibros 2014, 13(2):148-155.
115. Ling Y., Puel A. IL-17 and infections. Actas Dermosifiliogr 2014, 105(Suppl 1):34-40.
116. Nembrini C., Marsland B.J., Kopf M. IL-17-producing T cells in lung immunity and inflammation. J Allergy Clin Immunol 2009, 123(5):986-994. [quiz: 995-6].
117. Ye P., Garvey P.B., Zhang P., et al. Interleukin-17 and lung host defense against Klebsiella pneumoniae infection. Am J Respir Cell Mol Biol 2001, 25(3):335-340.
118. Lubberts E., van den Bersselaar L., Oppers-Walgreen B., et al. IL-17 promotes bone erosion in murine collagen-induced arthritis through loss of the receptor activator of NF-kappa B ligand/osteoprotegerin balance. J Immunol 2003, 170(5):2655-2662.
119. Decraene A., Willems-Widyastuti A., Kasran A., et al. Elevated expression of both mRNA and protein levels of IL-17A in sputum of stable cystic fibrosis patients. Respir Res 2010, 11:177.
120. Tan H.L., Rosenthal M. IL-17 in lung disease: friend or foe?. Thorax 2013, 68(8):788-790.
121. Chan Y.R., Chen K., Duncan S.R., et al. Patients with cystic fibrosis have inducible IL-17+IL-22+ memory cells in lung draining lymph nodes. J Allergy Clin Immunol 2013, 131(4):1117-1129. 1129.e1-5.
122. Newcomb D.C., Boswell M.G., Huckabee M.M., et al. IL-13 regulates Th17 secretion of IL-17A in an IL-10-dependent manner. J Immunol 2012, 188(3):1027-1035.
123. Cho J.S., Pietras E.M., Garcia N.C., et al. IL-17 is essential for host defense against cutaneous Staphylococcus aureus infection in mice. J Clin Invest 2010, 120(5):1762-1773.
124. Siegmann N., Worbs D., Effinger F., et al. Invariant natural killer T (iNKT) cells prevent autoimmunity, but induce pulmonary inflammation in cystic fibrosis. Cell Physiol Biochem 2014, 34(1):56-70.
125. Konstan M.W., Schluchter M.D., Xue W., et al. Clinical use of ibuprofen is associated with slower FEV1 decline in children with cystic fibrosis. Am J Respir Crit Care Med 2007, 176(11):1084-1089.
126. Mogayzel P.J., Naureckas E.T., Robinson K.A., Pulmonary Clinical Practice Guidelines Committee, et al. Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health. Am J Respir Crit Care Med 2013, 187(7):680-689.
127. Zhang P.X., Cheng J., Zou S., et al. Pharmacological modulation of the AKT/microRNA-199a-5p/CAV1 pathway ameliorates cystic fibrosis lung hyper-inflammation. Nat Commun 2015, 6:6221.
128. Eigen H., Rosenstein B.J., FitzSimmons S., et al. A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis. Cystic Fibrosis Foundation Prednisone Trial Group. J Pediatr 1995, 126(4):515-523.
129. Ross K.R., Chmiel J.F., Konstan M.W. The role of inhaled corticosteroids in the management of cystic fibrosis. Paediatr Drugs 2009, 11(2):101-113.
130. Konstan M., Krenicky J., Hilliard K., et al. A pilot study evaluating the effect of pioglitazone, simvastatin and ibuprofen on neutrophil migration in vivo in healthy subjects. Pediatr Pulmonol 2009, 289-290.
131. Moss R.B., Mayer-Hamblett N., Wagener J., et al. Randomized, double-blind, placebo-controlled, dose-escalating study of aerosolized interferon gamma-1b in patients with mild to moderate cystic fibrosis lung disease. Pediatr Pulmonol 2005, 39(3):209-218.
132. Bishop C., Hudson V.M., Hilton S.C., et al. A pilot study of the effect of inhaled buffered reduced glutathione on the clinical status of patients with cystic fibrosis. Chest 2005, 127(1):308-317.
133. Hartl D., Starosta V., Maier K., et al. Inhaled glutathione decreases PGE2 and increases lymphocytes in cystic fibrosis lungs. Free Radic Biol Med 2005, 39(4):463-472.
134. Conrad C., Lymp J., Thompson V., et al. Long-term treatment with oral N-acetylcysteine: affects lung function but not sputum inflammation in cystic fibrosis subjects. A phase II randomized placebo-controlled trial. J Cyst Fibros 2015, 14(2):219-227.
135. Moss R.B., Mistry S.J., Konstan M.W., et al. Safety and early treatment effects of the CXCR2 antagonist SB-656933 in patients with cystic fibrosis. J Cyst Fibros 2013, 12(3):241-248.
136. Gaggar A., Chen J., Chmiel J.F., et al. Inhaled alpha-proteinase inhibitor therapy in patients with cystic fibrosis. J Cyst Fibros 2015, [Epub ahead of print].
137. Gould N.S., Gauthier S., Kariya C.T., et al. Hypertonic saline increases lung epithelial lining fluid glutathione and thiocyanate: two protective CFTR-dependent thiols against oxidative injury. Respir Res 2010, 11:119.
138. Chandler J.D., Min E., Huang J., et al. Antiinflammatory and antimicrobial effects of thiocyanate in a cystic fibrosis mouse model. Am J Respir Cell Mol Biol 2015, 53(2):193-205.
139. Grasemann H., Grasemann C., Kurtz F., et al. Oral L-arginine supplementation in cystic fibrosis patients: a placebo-controlled study. Eur Respir J 2005, 25(1):62-68.
140. Nichols D.P., Ziady A.G., Shank S.L., et al. The triterpenoid CDDO limits inflammation in preclinical models of cystic fibrosis lung disease. Am J Physiol Lung Cell Mol Physiol 2009, 297(5):L828-L836.
141. Serhan C.N., Chiang N., Dalli J., et al. Lipid mediators in the resolution of inflammation. Cold Spring Harb Perspect Biol 2015, 7(2):a016311.
142. Ramsey B.W., Dorkin H.L., Eisenberg J.D., et al. Efficacy of aerosolized tobramycin in patients with cystic fibrosis. N Engl J Med 1993, 328(24):1740-1746.
143. Ratjen F., Saiman L., Mayer-Hamblett N., et al. Effect of azithromycin on systemic markers of inflammation in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa. Chest 2012, 142(5):1259-1266.
144. Saiman L., Mayer-Hamblett N., Anstead M., AZ0004 Macrolide Study Team, et al. Open-label, follow-on study of azithromycin in pediatric patients with CF uninfected with Pseudomonas aeruginosa. Pediatr Pulmonol 2012, 47(7):641-648.
145. Saiman L., Anstead M., Mayer-Hamblett N., AZ0004 Azithromycin Study Group, et al. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 2010, 303(17):1707-1715.
146. Cantin A.M., Hartl D., Konstan M.W., et al. Inflammation in cystic fibrosis lung disease: pathogenesis and therapy. J Cyst Fibros 2015, 14(4):419-430.
147. Accurso F.J., Rowe S.M., Clancy J.P., et al. Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N Engl J Med 2010, 363(21):1991-2003.
148. Wainwright C.E., Elborn J.S., Ramsey B.W., TRAFFIC Study Group, TRANSPORT Study Group, et al. Lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR. N Engl J Med 2015, 373(3):220-231.